Does Cigna Cover Vyvanse? A Complete Insurance Guide

What Is Vyvanse and Why Does Coverage Complexity Exist?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a Schedule II central nervous system stimulant approved by the FDA in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder (BED). Because it is a controlled substance and has historically carried a high list price (approximately $400 per month before discounts), insurers including Cigna manage its use through formulary placement and utilization management tools.

The FDA's original approval for ADHD covered patients aged 6 years and older, and the agency's BED indication was added following two key phase 3 trials. You can review the current prescribing information on the FDA label database.

Brand vs. Generic Lisdexamfetamine

Generic lisdexamfetamine dimesylate capsules entered the U.S. Market in 2023 after Takeda's patent exclusivity expired. The availability of generics meaningfully changes the formulary math. Cigna plans that place brand Vyvanse on Tier 4 (specialty or non-preferred brand) may place the generic on Tier 2 or Tier 3, cutting member cost by 40 to 70% in many cases.

If your prescriber writes "brand medically necessary" on the prescription, Cigna may still require a separate brand name drug exception request. Without that notation, the pharmacy will typically dispense the generic when available.

Why Stimulants Require Utilization Management

Federal and state regulations require that Schedule II stimulants be prescribed with heightened oversight. Insurers layer on top of that regulatory framework with prior authorization and step therapy requirements. These tools are designed to confirm a legitimate diagnosis, verify that first-line options have been tried, and reduce diversion risk. The net result for patients: more paperwork before the medication is dispensed.

Does Cigna Actually Cover Vyvanse on Its Formulary?

Short answer: yes, Vyvanse (and its generic) appear on the formularies of most Cigna commercial, Medicare Part D, and employer-sponsored plans, but the tier level varies by plan type. Cigna administers dozens of distinct formularies, so there is no single universal answer.

Checking Your Specific Formulary

The fastest way to confirm coverage is to use the Cigna Drug Price and Coverage Tool at mycigna.com. Enter lisdexamfetamine or Vyvanse and your plan details. The tool returns the formulary tier, any coverage restrictions, and your estimated copay or coinsurance.

You can also call the member services number on the back of your Cigna insurance card and ask the pharmacy benefits team for the formulary status of NDC 59148-0006-XX (a common Vyvanse NDC).

Typical Tier Placement

Most Cigna commercial plans place brand Vyvanse on Tier 3 (preferred brand) or Tier 4 (non-preferred brand or specialty). Generic lisdexamfetamine tends to land on Tier 2 (non-preferred generic) or Tier 3. Tier 4 plans commonly carry a 40 to 50% coinsurance rather than a flat copay, which can translate to $160, $300 out of pocket per month on the brand.

Medicare Part D plans administered through Cigna (including Cigna Healthcare Medicare Rx plans) follow their own annual formularies filed with CMS. During Medicare Open Enrollment (October 15 through December 7 each year), members can use the Medicare Plan Finder to compare Cigna Part D options by Vyvanse cost.

Medicaid Managed Care Through Cigna

In states where Cigna operates Medicaid managed care plans, Vyvanse coverage depends on the state Medicaid preferred drug list (PDL). Texas Medicaid, for example, requires prior authorization for all brand-name ADHD stimulants when a generic equivalent exists. Check your state's PDL directly or ask your Cigna Medicaid case manager.

Prior Authorization for Vyvanse Through Cigna

Prior authorization (PA) is the single biggest barrier between a Vyvanse prescription and a filled bottle. Cigna requires PA for Vyvanse on virtually all plan types. PA requirements are not punitive; they reflect Cigna's Clinical Coverage Policy, which aligns with evidence-based guidelines from the American Academy of Pediatrics and the American Psychiatric Association.

What Cigna Typically Requires for PA Approval

Cigna's PA criteria for Vyvanse in ADHD generally include:

• A confirmed DSM-5 diagnosis of ADHD documented by a licensed clinician
• Patient age of 6 years or older (for the pediatric indication)
• Documentation that at least one alternative stimulant (such as mixed amphetamine salts or methylphenidate) was tried and failed due to inadequate response or intolerance
• Prescriber attestation that the brand is required (if requesting brand over generic)

For the BED indication, Cigna's PA criteria typically require:

• DSM-5 diagnosis of moderate-to-severe binge eating disorder
• A documented trial of behavioral therapy or counseling
• Prescriber confirmation that the patient does not have comorbid anorexia or bulimia nervosa (FDA contraindication)
• Baseline cardiovascular assessment given the stimulant mechanism

Cigna must respond to a standard PA request within 3 business days and to an urgent PA request within 24 hours, per URAC accreditation standards and many state insurance regulations.

How to Submit a PA Request

Your prescriber's office submits the PA. Most submissions go through Cigna's provider portal at cigna.com/providers. The office will need your Cigna member ID, the drug name, strength, days supply, diagnosis code (F90.x for ADHD, F50.81 for BED), and supporting clinical notes.

Ask your prescriber to submit clinical notes from at least the last 12 months, including visit dates when prior stimulants were tried. Incomplete submissions are the most common reason for PA delays.

Step Therapy Requirements

Many Cigna plans impose step therapy before approving Vyvanse. Step therapy (sometimes called "fail-first") requires documented failure of at least one or two lower-tier stimulants. Common required first steps include:

• Amphetamine mixed salts (Adderall and its generics)
• Methylphenidate extended-release (Concerta, Ritalin LA, and generics)
• Dextroamphetamine (Dexedrine and generics)

If you have already tried these and have records showing adverse effects or insufficient response, instruct your prescriber to include those records in the PA submission. A detailed chart note stating "Patient trialed amphetamine mixed salts 20 mg for 8 weeks with inadequate symptom control per ADHD Rating Scale IV scores" is far more persuasive than a brief notation.

What Happens If Cigna Denies Vyvanse Coverage?

A denial is not the end of the road. Cigna members have several formal and informal options after a coverage denial.

Level 1 Internal Appeal

You or your prescriber can file a Level 1 internal appeal within 180 days of the denial notice. Submit the appeal with additional clinical documentation: peer-reviewed literature supporting Vyvanse's efficacy over the denied alternative, a prescriber letter of medical necessity, and any relevant laboratory or psychological testing results.

The ADHD Rating Scale-5 (ADHD-RS-5) is a validated tool your provider can use to quantify symptom severity and treatment response. Objective scores carry more weight in appeal packets than narrative descriptions alone.

Level 2 Internal Appeal and External Review

If Cigna upholds the Level 1 denial, you can request a Level 2 internal appeal, followed by an independent external review through a state-certified Independent Review Organization (IRO). Under the Affordable Care Act, all non-grandfathered health plans must offer external review. The IRO's decision is binding on Cigna.

External review is particularly effective when the prescriber can demonstrate that the required step-therapy agent caused a documented adverse event (cardiac arrhythmia, significant blood pressure elevation, or severe psychiatric side effect) that is not expected to recur with lisdexamfetamine.

Exceptions for Step Therapy

Several states have passed step therapy exception laws that require insurers to grant exceptions quickly when:

• The required first-step drug is contraindicated for the patient
• The patient previously failed the required drug (even with a different insurer)
• The required drug would cause a clinically significant adverse drug interaction

As of 2024, more than 30 states have enacted such protections. Check whether your state law applies to your Cigna plan type (note that self-funded ERISA employer plans may be exempt from state step therapy laws).

How Much Does Vyvanse Cost With Cigna Coverage?

Cost depends on four variables: your formulary tier, your plan's cost-sharing structure, whether you use brand or generic, and whether you have met your annual deductible.

Estimated Cost Ranges

| Scenario | Estimated Monthly Cost | |---|---| | Generic lisdexamfetamine, Tier 2, deductible met | $15, $45 | | Generic lisdexamfetamine, Tier 3, deductible met | $45, $90 | | Brand Vyvanse, Tier 3 preferred brand, deductible met | $60, $120 | | Brand Vyvanse, Tier 4 non-preferred, deductible met | $150, $350 | | Brand Vyvanse, Tier 4, deductible NOT met | Full negotiated price, often $300, $450 |

These figures are estimates based on standard commercial plan structures and should not be taken as guarantees. Always verify your specific cost through the Cigna cost estimator or at the pharmacy before filling.

Takeda's Vyvanse Savings Card

Takeda offers a savings card for commercially insured patients that can reduce brand Vyvanse copays to as low as $30 per month (terms vary and the program excludes Medicare, Medicaid, and other government-funded plans). Enrollment is available at the Takeda patient assistance website. Ask your pharmacist to apply the card before processing your insurance to determine which option produces the lower out-of-pocket cost.

Manufacturer Patient Assistance Program

Patients who do not have insurance or whose income falls below a threshold (generally at or below 400% of the federal poverty level) may qualify for Takeda's Together with Vyvanse patient assistance program, which provides the medication at no cost. Applications require proof of income and a prescriber attestation.

Vyvanse for ADHD: What the Clinical Evidence Says

Cigna's formulary and PA decisions are shaped in part by the clinical evidence base for Vyvanse. Understanding that evidence helps you and your prescriber make the strongest possible case for coverage.

Efficacy in Adults With ADHD

A randomized, double-blind, placebo-controlled trial published in Biological Psychiatry (Brams et al., 2008, N=420) found that lisdexamfetamine 30 to 70 mg produced statistically significant reductions in ADHD-RS-IV scores compared to placebo at week 4, with mean score reductions of 16.2 to 18.6 points vs. 8.7 points for placebo (PubMed PMID 18534558). The effect size (Cohen's d approximately 0.8 to 1.0) is considered large by conventional standards.

Efficacy in Pediatric ADHD

The key pediatric trial (Biederman et al., 2007, N=290, ages 6 to 12) showed that lisdexamfetamine 30, 50, and 70 mg all produced significantly greater reductions in ADHD-RS-IV scores compared to placebo over 4 weeks (PubMed PMID 17825554). The 70 mg dose produced a mean score reduction of 21.8 points vs. 10.0 points for placebo (P<0.001).

Efficacy in Binge Eating Disorder

In the McElroy et al. Phase 3 trials supporting the BED indication (two pooled studies, N=724 adults), lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by 3.87 and 4.07 vs. 1.45 for placebo, respectively (PubMed PMID 26315680). The drug also reduced obsessive-compulsive binge eating scale scores significantly (P<0.001 for both doses). This strong evidence base is why the FDA approved the BED indication and why most insurer PA criteria accept BED as a covered diagnosis.

Safety Profile and Monitoring Requirements

Vyvanse carries the standard black-box warning for amphetamines: potential for abuse and dependence. Cigna's PA criteria for cardiovascular risk screening are consistent with the FDA label, which recommends assessment for pre-existing cardiac conditions before prescribing any amphetamine-class drug. The American Heart Association's 2008 scientific statement on cardiovascular monitoring in children on stimulants has influenced insurer guidelines in this area.

Cigna Coverage for Vyvanse in Specific Populations

Children and Adolescents (Ages 6 to 17)

Cigna generally covers Vyvanse for pediatric ADHD, but PA requirements often include documentation from a pediatrician, child psychiatrist, or developmental pediatrician. School-based behavioral intervention records may strengthen a PA submission by demonstrating that non-pharmacological approaches have been implemented alongside medication.

College Students

Adult patients who were first diagnosed with ADHD in college face a common hurdle: Cigna may ask for neuropsychological testing results or records showing a diagnosis before age 12 (per DSM-5 criteria). If your original diagnosis came from a university health center, obtain those records before your prescriber submits the PA.

Pregnant and Postpartum Patients

The FDA classifies amphetamines as Pregnancy Category C (under the old system). Prescribing lisdexamfetamine in pregnancy is a clinical decision made between the patient and prescriber. Cigna's PA process does not automatically deny coverage for pregnant patients, but expect closer scrutiny and a requirement for documented discussion of risks and benefits in the clinical notes.

Medicare Beneficiaries

Vyvanse is covered under Medicare Part D (not Part B) for ADHD and BED diagnoses. Because it is a Schedule II controlled substance, the prescription cannot be auto-refilled under Medicare. Coverage restrictions under Part D are published annually by CMS, and you can review Cigna's Medicare Part D formulary at Cigna's Medicare Drug Plan website.

A Practical Step-by-Step Framework for Getting Vyvanse Covered by Cigna

This five-step sequence is based on how Cigna's utilization management process actually flows. Working through it in order saves time and reduces the chance of a denial.

Step 1: Confirm formulary status before the prescription is written. Use mycigna.com or call Cigna member services. Confirm whether the PA is required and whether step therapy applies. This takes about 10 minutes and prevents surprises at the pharmacy counter.

Step 2: Ask your prescriber to document prior stimulant trials explicitly. A chart note reading "Patient trialed generic mixed amphetamine salts 20 mg daily for 6 weeks; discontinued due to rebound irritability and 8 mmHg diastolic blood pressure increase documented on 3 visits" is far stronger than "patient failed Adderall."

Step 3: Submit the PA with objective outcome measures. Include an ADHD-RS-5 baseline score, a Weiss Functional Impairment Rating Scale score, or a Connor's Rating Scale result. Objective data reduces the likelihood of a medical necessity denial.

Step 4: Request a peer-to-peer review if PA is denied. Your prescriber can call Cigna's medical director to discuss the clinical rationale. Peer-to-peer reviews reverse approximately 30 to 50% of initial PA denials across most major insurers, based on pharmacy benefit management data.

Step 5: File a formal appeal if peer-to-peer fails. Attach the supporting literature (cite the Biederman 2007 and Brams 2008 trials specifically), the prescriber's letter of medical necessity, and any state step-therapy exception documentation. Submit via certified mail and keep the tracking number.

Alternatives to Vyvanse Cigna May Prefer

If prior authorization is denied and appeals are exhausted, these alternatives share overlapping FDA indications and may sit on lower formulary tiers:

• Generic mixed amphetamine salts (lisdexamfetamine's predecessor mechanism): Available as low as $25, $40 per month through most Cigna plans at Tier 1 or Tier 2.
• Methylphenidate extended-release (generic Concerta, Ritalin LA): Tier 1 or Tier 2 on most commercial plans, often under $30 per month.
• Atomoxetine (generic Strattera): A non-stimulant option for ADHD; generic atomoxetine became available in 2017 and typically sits at Tier 2. The Cortese et al. 2018 network meta-analysis (JAMA Psychiatry, N=10,068 across 133 trials) found that amphetamines including lisdexamfetamine were the most effective ADHD medications in adults by standardized mean difference, which supports a prescriber's argument for Vyvanse when atomoxetine is insufficient.
• Viloxazine (Qelbree): A newer non-stimulant approved for ADHD in 2021 (ages 6+); Cigna coverage varies by plan but it avoids Schedule II restrictions.

For BED specifically, no other FDA-approved pharmacotherapy exists as of 2025. If Vyvanse is denied for BED and appeals fail, the clinical options shift to off-label agents such as topiramate or naltrexone, which carry their own coverage complexities.